PMID- 36266209
OWN - NLM
STAT- MEDLINE
DCOM- 20230201
LR  - 20230325
IS  - 1878-3562 (Electronic)
IS  - 1590-8658 (Print)
IS  - 1590-8658 (Linking)
VI  - 55
IP  - 2
DP  - 2023 Feb
TI  - Spike-specific humoral and cellular immune responses after COVID-19 mRNA 
      vaccination in patients with cirrhosis: A prospective single center study.
PG  - 160-168
LID - S1590-8658(22)00701-0 [pii]
LID - 10.1016/j.dld.2022.09.010 [doi]
AB  - BACKGROUND AND AIMS: COVID-19 mRNA vaccines were approved to prevent severe forms 
      of the disease, but their immunogenicity and safety in cirrhosis is poorly known. 
      METHOD: In this prospective single-center study enrolling patients with cirrhosis 
      undergoing COVID-19 vaccination (BNT162b2 and mRNA-1273), we assessed humoral and 
      cellular responses vs healthy controls, the incidence of breakthrough infections 
      and adverse events (AEs). Antibodies against spike- and nucleocapsid-protein 
      (anti-S and anti-N) and Spike-specific T-cells responses were quantified at 
      baseline, 21 days after the first and second doses and during follow-up. RESULTS: 
      182 cirrhotics (85% SARS-CoV-2-naive) and 38 controls were enrolled. After 2 
      doses of vaccine, anti-S titres were significantly lower in cirrhotics vs 
      controls [1,751 (0.4-25,000) U/mL vs 4,523 (259-25,000) U/mL, p=0.012] and in 
      SARS-CoV-2-naive vs previously infected cirrhotics [999 (0.4-17,329) U/mL vs 
      7,500 (12.5-25,000) U/mL, (p<0.001)]. T-cell responses in cirrhotics were similar 
      to controls, although with different kinetics. In SARS-CoV-2-naive cirrhotics, 
      HCC, Child-Pugh B/C and BNT162b2 were independent predictors of low response. 
      Neither unexpected nor severe AEs emerged. During follow-up, 2% turned SARS-CoV-2 
      positive, all asymptomatic. CONCLUSION: Humoral response to COVID-19 vaccines 
      appeared suboptimal in patients with cirrhosis, particularly in SARS-CoV-2-naive 
      decompensated cirrhotics, although cellular response appeared preserved, and low 
      breakthrough infections rate was registered.
CI  - Copyright (c) 2022 Editrice Gastroenterologica Italiana S.r.l. Published by 
      Elsevier Ltd. All rights reserved.
FAU - Iavarone, Massimo
AU  - Iavarone M
AD  - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of 
      Gastroenterology and Hepatology, Milan, Italy. Electronic address: 
      massimo.iavarone@policlinico.mi.it.
FAU - Tosetti, Giulia
AU  - Tosetti G
AD  - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of 
      Gastroenterology and Hepatology, Milan, Italy.
FAU - Facchetti, Floriana
AU  - Facchetti F
AD  - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of 
      Gastroenterology and Hepatology, Milan, Italy.
FAU - Topa, Matilde
AU  - Topa M
AD  - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of 
      Gastroenterology and Hepatology, Milan, Italy.
FAU - Er, Joey Ming
AU  - Er JM
AD  - Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.
FAU - Hang, Shou Kit
AU  - Hang SK
AD  - Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.
FAU - Licari, Debora
AU  - Licari D
AD  - Clinical Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
FAU - Lombardi, Andrea
AU  - Lombardi A
AD  - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore 
      Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, 
      University of Milano, Milano, Italy.
FAU - D'Ambrosio, Roberta
AU  - D'Ambrosio R
AD  - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of 
      Gastroenterology and Hepatology, Milan, Italy.
FAU - Degasperi, Elisabetta
AU  - Degasperi E
AD  - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of 
      Gastroenterology and Hepatology, Milan, Italy.
FAU - Loglio, Alessandro
AU  - Loglio A
AD  - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of 
      Gastroenterology and Hepatology, Milan, Italy.
FAU - Oggioni, Chiara
AU  - Oggioni C
AD  - IRCCS Humanitas Research Hospital, Quality and Patient Safety Unit, Rozzano, 
      Milano, Italy.
FAU - Perbellini, Riccardo
AU  - Perbellini R
AD  - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of 
      Gastroenterology and Hepatology, Milan, Italy.
FAU - Caccia, Riccardo
AU  - Caccia R
AD  - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of 
      Gastroenterology and Hepatology, Milan, Italy.
FAU - Bandera, Alessandra
AU  - Bandera A
AD  - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore 
      Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, 
      University of Milano, Milano, Italy.
FAU - Gori, Andrea
AU  - Gori A
AD  - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore 
      Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, 
      University of Milano, Milano, Italy.
FAU - Ceriotti, Ferruccio
AU  - Ceriotti F
AD  - Clinical Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milan, Italy.
FAU - Scudeller, Luigia
AU  - Scudeller L
AD  - Research and Innovation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 
      Bologna, Italy.
FAU - Bertoletti, Antonio
AU  - Bertoletti A
AD  - Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; 
      Singapore Immunology Network, A*STAR, Singapore.
FAU - Lampertico, Pietro
AU  - Lampertico P
AD  - Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of 
      Gastroenterology and Hepatology, Milan, Italy; CRC "A. M. and A. Migliavacca" 
      Center for Liver Disease, Department of Pathophysiology and Transplantation, 
      University of Milan, Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20221017
PL  - Netherlands
TA  - Dig Liver Dis
JT  - Digestive and liver disease : official journal of the Italian Society of 
      Gastroenterology and the Italian Association for the Study of the Liver
JID - 100958385
RN  - 0 (Antibodies)
RN  - 0 (Antibodies, Viral)
RN  - 0 (BNT162 Vaccine)
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Humans
MH  - Antibodies
MH  - Antibodies, Viral
MH  - BNT162 Vaccine
MH  - Breakthrough Infections
MH  - *Carcinoma, Hepatocellular
MH  - *COVID-19/prevention & control
MH  - *COVID-19 Vaccines/adverse effects
MH  - Immunity, Cellular
MH  - Liver Cirrhosis
MH  - *Liver Neoplasms
MH  - Prospective Studies
MH  - RNA, Messenger
MH  - SARS-CoV-2
MH  - Vaccination
PMC - PMC9575378
OTO - NOTNLM
OT  - Hepatitis B
OT  - Hepatitis C
OT  - Hepatocellular carcinoma
OT  - Moderna mRNA-1273
OT  - Nucleocapsid-protein
OT  - Pfizer-BioNTech BNT162b2
OT  - Portal hypertension
OT  - SARS-CoV-2
OT  - Spike-protein
COIS- Conflict of interest MI: Speaking/Teaching, consultant and advisory board for 
      Bayer, Gilead Sciences, BMS, Janssen, Ipsen, MSD, BTG-Boston Scientific, AbbVie, 
      Guerbet, EISAI, Roche. BA: A patent for a method to monitor SARS-CoV-2-specific 
      T-cells in biological samples pending. PL: Advisory Board/Speaker Bureau for BMS, 
      ROCHE, GILEAD SCIENCES, GSK, ABBVIE, MSD, ARROWHEAD, ALNYLAM, JANSSEN, SBRING 
      BANK, MYR, EIGER, ALIGOS, ANTIOS, VIR.
EDAT- 2022/10/21 06:00
MHDA- 2023/02/01 06:00
PMCR- 2022/10/17
CRDT- 2022/10/20 22:08
PHST- 2022/06/21 00:00 [received]
PHST- 2022/09/10 00:00 [revised]
PHST- 2022/09/12 00:00 [accepted]
PHST- 2022/10/21 06:00 [pubmed]
PHST- 2023/02/01 06:00 [medline]
PHST- 2022/10/20 22:08 [entrez]
PHST- 2022/10/17 00:00 [pmc-release]
AID - S1590-8658(22)00701-0 [pii]
AID - 10.1016/j.dld.2022.09.010 [doi]
PST - ppublish
SO  - Dig Liver Dis. 2023 Feb;55(2):160-168. doi: 10.1016/j.dld.2022.09.010. Epub 2022 
      Oct 17.